CN113244122B - 一种双组份精华面霜 - Google Patents
一种双组份精华面霜 Download PDFInfo
- Publication number
- CN113244122B CN113244122B CN202110279532.3A CN202110279532A CN113244122B CN 113244122 B CN113244122 B CN 113244122B CN 202110279532 A CN202110279532 A CN 202110279532A CN 113244122 B CN113244122 B CN 113244122B
- Authority
- CN
- China
- Prior art keywords
- component
- certain amount
- water
- soluble active
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006071 cream Substances 0.000 title claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 95
- 229920000642 polymer Polymers 0.000 claims abstract description 74
- 239000000243 solution Substances 0.000 claims abstract description 41
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 12
- 229910021642 ultra pure water Inorganic materials 0.000 claims abstract description 11
- 239000012498 ultrapure water Substances 0.000 claims abstract description 11
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 239000002562 thickening agent Substances 0.000 claims abstract description 9
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 7
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 229940106189 ceramide Drugs 0.000 claims abstract description 7
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 7
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 7
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000741 silica gel Substances 0.000 claims description 30
- 229910002027 silica gel Inorganic materials 0.000 claims description 30
- 239000002244 precipitate Substances 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 9
- -1 modified phosphate ester Chemical class 0.000 claims description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960004889 salicylic acid Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 8
- 230000003266 anti-allergic effect Effects 0.000 claims description 8
- 125000003700 epoxy group Chemical group 0.000 claims description 8
- 238000010526 radical polymerization reaction Methods 0.000 claims description 7
- CUDYYMUUJHLCGZ-UHFFFAOYSA-N 2-(2-methoxypropoxy)propan-1-ol Chemical compound COC(C)COC(C)CO CUDYYMUUJHLCGZ-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 229940080421 coco glucoside Drugs 0.000 claims description 4
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 4
- 229940104261 taurate Drugs 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 3
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 3
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 239000001913 cellulose Chemical group 0.000 claims description 3
- 229920002678 cellulose Chemical group 0.000 claims description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000000230 xanthan gum Chemical group 0.000 claims description 3
- 229920001285 xanthan gum Chemical group 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims 1
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 1
- 239000001570 sorbitan monopalmitate Substances 0.000 claims 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 15
- 230000008859 change Effects 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 239000000178 monomer Substances 0.000 abstract 1
- 230000000379 polymerizing effect Effects 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen
- C08F220/606—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen and containing other heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/06—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
- C08F226/10—N-Vinyl-pyrrolidone
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/882—Mixing prior to application
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种双组份精华面霜。分为A、B组分,其中A组分为活性成分的水溶液,B组分为活性成分的油性溶液。其中A组分中活性成分为一种水溶性聚合物,是由多种活性单体通过自由基聚合而成,还包含神经酰胺、泛酸、β‑葡萄糖,剩余成分为超纯水。其中B组分包含油溶性活性聚合物、抗敏活性肽、醇类物质,增稠剂,乳化剂。能够以任意比例混合使用,让使用者平衡对“保湿”和“不油”的需求,无需因为换季而更换化妆品品牌以及牌号。
Description
技术领域
本发明涉及化妆品领域,更具体的是一种双组份精华面霜。
背景技术
以女性消费者作为目标顾客群或营销对象已成为商家的共识,因 为当今世界女性消费在经济生活中发挥着越来越重大的作用,研究女 性消费行为可以为企业及时制定出满足最大效益的营销策略,为商家 壮大经济实力提供指导。女性消费行为不只是单纯的购买活动,它是 在一定的历史文化背景下,由各方面因素综合作用而形成的复杂行 为。女性化妆品消费市场,尤其都市女性化妆品消费市场是一个潜力 极大的广阔市场。
我国的化妆品行业兴起于上世纪80年代,迅猛发展于90年代。 尤其1997年以来,化妆品行业年度销售额的平均增幅超过了10%, 年度利润指标的平均增幅也超过了10%,部分年度甚至达到了20%。 而中国在2006年全球化妆品销售额排名中上升了两位,超越了法国 和德国,目前已经成为全球第三大化妆品市场。
现今年轻女性更愿意自己动手进行DIY,能够自己掌握自己的皮 肤。目前市场上并没有产品能够满足她们的需求,品牌方会退出不同 牌号的产品以应对不同季节情况,但会导致瓶瓶罐罐越来越多。
发明内容
为了解决上述问题,本发明公开了一种双组份精华面霜,分为A、B组分,其中A组分为活性成分的水溶液,B组分为活性成分的油性溶液。
作为本发明一种双组份精华面霜的进一步方案,本发明A组分具体包含:水溶性活性聚合物0.1-3%,神经酰胺0.05-3%、泛酸0.1-3%、β-葡萄糖0.1-5%,剩余成分为超纯水。
作为本发明一种双组份精华面霜的进一步方案,本发明A组分中所有原料均为医药级,满足化妆品原料使用标准。
作为本发明一种双组份精华面霜的进一步方案,本发明B组分具体包含:油溶性活性聚合物5-10%,抗敏活性肽5-10%、醇类物质80-95%,增稠剂1-5%,乳化剂1-5%。
作为本发明一种双组份精华面霜的进一步方案,本发明A组分中 水溶性活性聚合物的结构如下所述:
作为本发明一种双组份精华面霜的进一步方案,本发明A组分中水溶性活性聚合物结构的制备方法,包含以下步骤:
(1)将一定量的医药级水杨酸和一定量的医药级甲基丙烯酸缩水甘油酯加入反应器中,持续反应,直至环氧基完全反应完,得到中间体A;
(2)将一定量的中间体A、一定量的医药级丙烯酰二甲基牛磺酸铵、一定量的医药级乙烯基吡咯烷酮、一定量的预处理过的偶氮二异丁腈加入到乙酸乙酯中,搅拌均匀;
(3)将(2)中所得液体于60-80℃下滴加到反应器中,进行自由基聚合,滴加完成后保温反应;
(4)将上述聚合物溶液通过电子级硅胶柱。;
(5)将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;
(6)过滤得到沉淀颗粒,重复步骤(5)三次以上。
作为本发明A组分中水溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(1)中医药级水杨酸和医药级甲基丙烯酸缩水甘油酯的添加比例为摩尔比,医药级水杨酸比医药级甲基丙烯酸缩水甘油酯为1.05:1-1.2:1。
具体的,步骤(1)中需要保证医药级甲基丙烯酸缩水甘油酯中环氧基被完全反应。
作为本发明A组分中水溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(2)中的中间体A、医药级丙烯酰二甲基牛磺酸铵、医药级乙烯基吡咯烷酮占比为中间体A的含量为10-25%,医药级丙烯酰二甲基牛磺酸铵的含量为30-50%,医药级乙烯基吡咯烷酮的含量为30-50%。
作为本发明A组分中水溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(2)中偶氮二异丁腈的预处理方法为使用医药级乙醇重结晶2-3次。
具体的,预处理方法为将20g偶氮二异丁腈加入到100g乙醇中,在60℃搅拌直至偶氮二异丁腈全部溶解,将体系温度降低到10℃,过滤得到偶氮二异丁腈晶体,反复2-3次即得到所需预处理过的偶氮二异丁腈。
作为本发明A组分中水溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(4)中电子级硅胶柱为使用默克200目硅胶,通过硅胶柱能够去除体系中金属离子以及小分子聚合物。
作为本发明A组分中水溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(5)中乙醇的用量为聚合物溶液的10-20倍。
作为本发明一种双组份精华面霜的进一步方案,本发明A组分中水溶性活性聚合物的分子量Mw为50000-100000。
作为本发明一种双组份精华面霜的进一步方案,本发明B组分中 油溶性活性聚合物的结构如下所示:
作为本发明B组分中油溶性活性聚合物结构,结构式中x为 10-18。
作为本发明B组分中油溶性活性聚合物结构,结构式中R可以为 如下结构中的一种或多种:
作为本发明B组分中油溶性活性聚合物结构的制备方法包含以下步骤:
(1)将一定量的长链烷烃酸和一定量的谷氨酸加入到反应器中,在一定温度下反应完全;
(2)将选择的R基团以及一定量的溶剂二丙二醇甲醚加入到体系中,在甲基磺酸的催化下进行反应,直至反应完全;
(3)通过水洗去除催化剂;
(4)将上述聚合物溶液通过电子级硅胶柱;
(5)将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;
(6)过滤得到沉淀颗粒,重复步骤(5)三次以上。
作为本发明B组分中油溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(1)中长链烷烃酸和谷氨酸的添加量为摩尔比1:1.5-1:2。
作为本发明B组分中油溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(2)中溶剂二丙二醇甲醚的添加比例为总质量的50%。
作为本发明B组分中油溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(3)中水洗的方法为使用总质量1-1.5倍的超纯水混合搅拌后进行分液,分液完成后分离掉水层,此过程反复3-4次。
作为本发明B组分中油溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(4)中电子级硅胶柱为使用默克200目硅胶,通过硅胶柱能够去除体系中金属离子以及小分子聚合物。
作为本发明B组分中油溶性活性聚合物结构制备方法的进一步方案,上述制备方法步骤(5)中中乙醇的用量为聚合物溶液的10-20倍。
作为本发明一种双组份精华面霜的进一步方案,本发明B组分中油溶性活性聚合物的分子量Mw为10000-50000。
作为本发明一种双组份精华面霜的进一步方案,本发明B组分中 抗敏活性肽为乙酰基四肽、乙酰基二肽、乙酰基六肽、棕榈酰三肽中的一种或多种。
作为本发明一种双组份精华面霜的进一步方案,本发明B组分中 醇类物质为乙醇、二甘醇、1 ,3-丙二醇、甘油、丁二醇、1 ,2-戊二醇、1 ,2-己二醇、聚乙二醇中的一种或多种混合物。
作为本发明一种双组份精华面霜的进一步方案,本发明B组分中增稠剂为卡波姆、黄原胶、纤维素及其改性物、淀粉改性磷酸酯。
作为本发明一种双组份精华面霜的进一步方案,本发明B组分中中乳化剂为单月桂酸失水山梨醇酯、聚氧乙烯单月桂酸失水山梨醇酯、单棕榈酸失水山梨醇酯、聚氧乙烯单棕榈酸失水山梨醇酯、甘油硬脂酸脂、蔗糖多硬脂酸脂、聚甘油二硬脂酸脂、椰油基葡萄苷中的一种或多种混合物。
作为本发明一种双组份精华面霜使用方法的进一步方案,本发明能够让使用者根据当前天气情况以及自身情况自行配置精华面霜。
本发明提供的技术方案带来的有益效果是:
添加两种活性成分,能够处理肌肤基础问题(如敏感、干燥、痘痘),120小时持续提供肌肤水能量,刺激皮肤水合作用,活性聚合物能够增强皮肤全效屏障,形成“三重防御”的作用。
满足用户对肌肤质感的更高追求(如细腻、透白、抗衰)且起速更快,性能持续稳定。独特的双锁肽键可大幅增强活性物的生物利用率,从而满足目标需求。
双组分精华面霜,能够让使用者平衡对“保湿”和“不油”的需求,无需因为换季而更换化妆品品牌以及牌号。
具体实施方法
以下将通过具体实施例进一步地描述本发明。
在以下具体实施例中,所涉及的操作未注明条件者,均按照常规条件或者制造商建议的条件进行。本发明方案中所用原料购自国药试剂以及阿拉丁试剂。
合成例1
将20g偶氮二异丁腈加入到含有100g乙醇的锥形瓶中,在锥形瓶上接球型冷凝管,开启常温冷凝水循环,锥形瓶中使用磁力搅拌子在60℃搅拌,直至偶氮二异丁腈全部溶解,撤去热源,将体系温度降低到10℃,使用双层滤纸过滤得到偶氮二异丁腈晶体。
反复2-3次即得到所需预处理过的偶氮二异丁腈。
合成例2
将138g的医药级水杨酸和142g的医药级甲基丙烯酸缩水甘油酯加入反应器中,在50℃下持续反应,直至环氧基完全反应完,得到中间体A1;
将20g的中间体A1、45g的医药级丙烯酰二甲基牛磺酸铵、35g的医药级乙烯基吡咯烷酮、0.3g预处理过的偶氮二异丁腈加入到100g的乙酸乙酯中,搅拌均匀。将上述液体滴加到反应器中,于70℃下进行自由基聚合,滴加完成后保温70℃反应2小时;
使用50g的默克200目硅胶填充层析柱,将所得的聚合物溶液进行柱层析;
将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;
过滤得到沉淀颗粒,重复使用医药级乙醇处理三次以上。最终得到A组分中水溶性活性聚合物1。
合成例3
将149g的医药级水杨酸和142g的医药级甲基丙烯酸缩水甘油酯加入反应器中,在50℃下持续反应,直至环氧基完全反应完,得到中间体A2;
将15g的中间体A2、45g的医药级丙烯酰二甲基牛磺酸铵、40g的医药级乙烯基吡咯烷酮、0.5g预处理过的偶氮二异丁腈加入到100g的乙酸乙酯中,搅拌均匀。将上述液体滴加到反应器中,于70℃下进行自由基聚合,滴加完成后保温70℃反应2小时;
使用50g的默克200目硅胶填充层析柱,将所得的聚合物溶液进行柱层析;
将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;
过滤得到沉淀颗粒,重复使用医药级乙醇处理三次以上。最终得到A组分中水溶性活性聚合物2。
合成例4
将170g的医药级水杨酸和142g的医药级甲基丙烯酸缩水甘油酯加入反应器中,在50℃下持续反应,直至环氧基完全反应完,得到中间体A3;
将25g的中间体A3、35g的医药级丙烯酰二甲基牛磺酸铵、40g的医药级乙烯基吡咯烷酮、1g预处理过的偶氮二异丁腈加入到100g的乙酸乙酯中,搅拌均匀。将上述液体滴加到反应器中,于70℃下进行自由基聚合,滴加完成后保温70℃反应2小时;
使用50g的默克200目硅胶填充层析柱,将所得的聚合物溶液进行柱层析;
将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;
过滤得到沉淀颗粒,重复使用医药级乙醇处理三次以上。最终得到A组分中水溶性活性聚合物3。
合成例5
将156g的医药级水杨酸和142g的医药级甲基丙烯酸缩水甘油酯加入反应器中,在50℃下持续反应,直至环氧基完全反应完,得到中间体A4;
将10g的中间体A4、50g的医药级丙烯酰二甲基牛磺酸铵、40g的医药级乙烯基吡咯烷酮、0.7g预处理过的偶氮二异丁腈加入到100g的乙酸乙酯中,搅拌均匀。将上述液体滴加到反应器中,于70℃下进行自由基聚合,滴加完成后保温70℃反应2小时;
使用50g的默克200目硅胶填充层析柱,将所得的聚合物溶液进行柱层析;
将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;
过滤得到沉淀颗粒,重复使用医药级乙醇处理三次以上。最终得到A组分中水溶性活性聚合物4。
合成例6
将165g的医药级水杨酸和142g的医药级甲基丙烯酸缩水甘油酯加入反应器中,在50℃下持续反应,直至环氧基完全反应完,得到中间体A5;
将25g的中间体A5、50g的医药级丙烯酰二甲基牛磺酸铵、25g的医药级乙烯基吡咯烷酮、1.5g预处理过的偶氮二异丁腈加入到100g的乙酸乙酯中,搅拌均匀。将上述液体滴加到反应器中,于70℃下进行自由基聚合,滴加完成后保温70℃反应2小时;
使用50g的默克200目硅胶填充层析柱,将所得的聚合物溶液进行柱层析;
将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;
过滤得到沉淀颗粒,重复使用医药级乙醇处理三次以上。最终得到A组分中水溶性活性聚合物5。
合成例7
将1摩尔的十四酸和1.5摩尔的谷氨酸加入到反应器中,在50℃下反应完全;
将0.5摩尔的R1基团以及200g的溶剂二丙二醇甲醚加入到体系中,加入0.5g的甲基磺酸作为催化剂,在80℃下进行反应,直至反应完全;
将300g的超纯水加入到体系中,混合搅拌后进行分液,分液完成后分离掉水层,此过程反复3-4次。
使用50g的默克200目硅胶填充层析柱,将所得的聚合物溶液进行柱层析;
将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;过滤得到沉淀颗粒,重复使用医药级乙醇处理三次以上。最终得到B组分中油溶性活性聚合物1。
合成例8
将1摩尔的十六酸和1.7摩尔的谷氨酸加入到反应器中,在50℃下反应完全;
将0.7摩尔的R2基团以及200g的溶剂二丙二醇甲醚加入到体系中,加入0.5g的甲基磺酸作为催化剂,在80℃下进行反应,直至反应完全;
将300g的超纯水加入到体系中,混合搅拌后进行分液,分液完成后分离掉水层,此过程反复3-4次。
使用50g的默克200目硅胶填充层析柱,将所得的聚合物溶液进行柱层析;
将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;过滤得到沉淀颗粒,重复使用医药级乙醇处理三次以上。最终得到B组分中油溶性活性聚合物2。
合成例9
将1摩尔的十八酸和2摩尔的谷氨酸加入到反应器中,在50℃下反应完全;
将1摩尔的R3基团以及200g的溶剂二丙二醇甲醚加入到体系中,加入0.5g的甲基磺酸作为催化剂,在80℃下进行反应,直至反应完全;
将300g的超纯水加入到体系中,混合搅拌后进行分液,分液完成后分离掉水层,此过程反复3-4次。
使用50g的默克200目硅胶填充层析柱,将所得的聚合物溶液进行柱层析;
将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;过滤得到沉淀颗粒,重复使用医药级乙醇处理三次以上。最终得到B组分中油溶性活性聚合物3。
实施例1:
将3g的水溶性活性聚合物1,0.5g的神经酰胺,1g的泛酸,4g的β-葡萄糖以及91.5g的超纯水加入到反应器中,在5℃下搅拌均匀,得到A组分。
将7g的油溶性活性聚合物1,5g抗敏活性肽乙酰基四肽、2g棕榈酰三肽、40g的1 ,2-戊二醇,40g的甘油,3g的增稠剂卡波姆,3g的乳化剂聚氧乙烯单月桂酸失水山梨醇酯加入到反应器中,在5℃下搅拌均匀,得到B组分。
实施例2:
将2g的水溶性活性聚合物2,1.5g的神经酰胺,2g的泛酸,5g的β-葡萄糖以及88.5g的超纯水加入到反应器中,在5℃下搅拌均匀,得到A组分。
将7g的油溶性活性聚合物2,3g抗敏活性肽乙酰基二肽、5g棕榈酰三肽、34g的1 ,2-戊二醇,10g的二甘醇,15g的乙醇,20g的甘油,3g的增稠剂纤维素及其改性物,3g的乳化剂椰油基葡萄苷加入到反应器中,在5℃下搅拌均匀,得到B组分。
实施例3:
将1.5g的水溶性活性聚合物3,1.5g的水溶性活性聚合物4,2g的神经酰胺,2.5g的泛酸,3g的β-葡萄糖以及89.5g的超纯水加入到反应器中,在5℃下搅拌均匀,得到A组分。
将10g的油溶性活性聚合物3,5g抗敏活性肽乙酰基四肽、3g乙酰基六肽、20g的1 ,2-己二醇,10g的乙醇36g的1 ,3-丙二醇,3g的增稠剂卡波姆,3g的乳化剂椰油基葡萄苷加入到反应器中,在5℃下搅拌均匀,得到B组分。
实施例4:
将3g的水溶性活性聚合物5,0.5g的神经酰胺,2g的泛酸,2g的β-葡萄糖以及92.5g的超纯水加入到反应器中,在5℃下搅拌均匀,得到A组分。
将10g的油溶性活性聚合物1,5g抗敏活性肽乙酰基四肽、5g棕榈酰三肽、25g的1 ,2-戊二醇,10g的聚乙二醇200,5g的乙醇,40g的甘油,3g的增稠剂黄原胶,3g的乳化剂蔗糖多硬脂酸脂加入到反应器中,在5℃下搅拌均匀,得到B组分。
以上所述仅为本发明的较佳实施例,并不用以限制本发明的保护范围,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
依据《化妆品安全技术规范》(2015版)规定的人体皮肤斑贴试验进行人体皮肤封闭型斑贴测试。
将加有受试物的斑试器帖敷与受试者背部皮肤,持续24h。受试物为化妆品产品物时,对照孔为空白对照(不置任何物质),受试物为稀释后的化妆品时,对照孔内使用该化妆品的稀释剂。分别于去除受试物斑试器后30min(待压痕消失后)、24h、48h按皮肤封闭型斑贴试验皮肤反应分级标准对皮肤进行评分。 测试人数为20人,年龄分布为18-50周岁的女性。
测试实施例1-4,A,B组分各占50%。
测试结果中0级为无反应,1级为微红色疑似过敏,2级为明显红疹,3级为出现疱
疹。
0级人数 | 1级人数 | 2级人数 | 3级人数 | |
实施例1 | 20 | 0 | 0 | 0 |
实施例2 | 20 | 0 | 0 | 0 |
实施例3 | 20 | 0 | 0 | 0 |
实施例4 | 20 | 0 | 0 | 0 |
对照1 | 20 | 0 | 0 | 0 |
对照2 | 20 | 0 | 0 | 0 |
对照3 | 20 | 0 | 0 | 0 |
对照4 | 20 | 0 | 0 | 0 |
从上表可以看出,本发明完全不会引起过敏。
本发明为一种双组分精华面霜,能够让使用者平衡对“保湿”和“不油”的需求,无需因为换季而更换化妆品品牌以及牌号。
Claims (3)
1.一种双组分精华面霜,其特征在于:所述分为A、B组分,其中A组分为活性成分的水溶液,B组分为活性成分的油性溶液,
A组分具体包含:水溶性活性聚合物0.1-3%,神经酰胺0.05-3%、泛酸0.1-3%、β-葡萄糖0.1-5%,剩余成分为超纯水,
B组分具体包含:油溶性活性聚合物5-10%,抗敏活性肽5-10%、醇类物质80-95%,增稠剂1-5%,乳化剂1-5%,
B组分中油溶性活性聚合物的结构如下所示:
所述结构式中x为10-18,所述结构式中R为如下结构中的一种或多种:
所述B组分中抗敏活性肽为乙酰基四肽、乙酰基二肽、乙酰基六肽、棕榈酰三肽中的一种或多种,
所述B组分中醇类物质为乙醇、二甘醇、1,3-丙二醇、甘油、丁二醇、1,2-戊二醇、1,2-己二醇、聚乙二醇中的一种或多种混合物,
所述B组分中增稠剂为卡波姆、黄原胶、纤维素及其改性物或淀粉改性磷酸酯,
所述B组分中乳化剂为单月桂酸失水山梨醇酯、聚氧乙烯单月桂酸失水山梨醇酯、单棕榈酸失水山梨醇酯、聚氧乙烯单棕榈酸失水山梨醇酯、甘油硬脂酸脂、蔗糖多硬脂酸脂、聚甘油二硬脂酸脂、椰油基葡萄糖苷中的一种或多种混合物。
2.权利要求1所述的一种双组分精华面霜的制备方法,其特征在于:A组分中水溶性活性聚合物结构的制备方法包含以下步骤:(1)将一定量的医药级水杨酸和一定量的医药级甲基丙烯酸缩水甘油酯加入反应器中,持续反应,直至环氧基完全反应完,得到中间体A;(2)将一定量的中间体A、一定量的医药级丙烯酰二甲基牛磺酸铵、一定量的医药级乙烯基吡咯烷酮、一定量的预处理过的偶氮二异丁腈加入到乙酸乙酯中,搅拌均匀;(3)将(2)中所得液体于60-80℃下滴加到反应器中,进行自由基聚合,滴加完成后保温反应;(4)将上述聚合物溶液通过电子级硅胶柱;(5)将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;(6)过滤得到沉淀颗粒,重复步骤(5)三次以上。
3.权利要求1所述的一种双组分精华面霜的制备方法,其特征在于:B组分中油溶性活性聚合物结构的制备方法包含以下步骤:(1)将一定量的长链烷烃酸和一定量的谷氨酸加入到反应器中,在一定温度下反应完全;(2)将选择的R基团以及一定量的溶剂二丙二醇甲醚加入到体系中,在甲基磺酸的催化下进行反应,直至反应完全;(3)通过水洗去除催化剂;(4)将上述聚合物溶液通过电子级硅胶柱;(5)将过完硅胶柱的聚合物溶液缓慢滴加到医药级乙醇溶液中,随着搅拌出现颗粒状沉淀;(6)过滤得到沉淀颗粒,重复步骤(5)三次以上。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110279532.3A CN113244122B (zh) | 2021-03-16 | 2021-03-16 | 一种双组份精华面霜 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110279532.3A CN113244122B (zh) | 2021-03-16 | 2021-03-16 | 一种双组份精华面霜 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113244122A CN113244122A (zh) | 2021-08-13 |
CN113244122B true CN113244122B (zh) | 2022-03-15 |
Family
ID=77181011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110279532.3A Active CN113244122B (zh) | 2021-03-16 | 2021-03-16 | 一种双组份精华面霜 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113244122B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009079889A1 (en) * | 2007-12-21 | 2009-07-02 | Changzhou Zhongke Laifang Power Science & Technology Co., Ltd. | Non-woven fabric reinforced microporous polymer membrane, manufacturing method and use thereof |
CN110227052A (zh) * | 2019-06-19 | 2019-09-13 | 杭州悦萱堂化妆品有限公司 | 一种保湿修复面霜及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR102015032910B1 (pt) * | 2015-12-29 | 2021-03-09 | Companhia Nitro Química Brasileira | processo de obtenção de uma dispersão coloidal, dispersão coloidal e seu uso |
CN107793573B (zh) * | 2017-10-13 | 2020-08-11 | 江南大学 | 一种杂化双亲性星型共聚物纳米胶束的制备方法 |
-
2021
- 2021-03-16 CN CN202110279532.3A patent/CN113244122B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009079889A1 (en) * | 2007-12-21 | 2009-07-02 | Changzhou Zhongke Laifang Power Science & Technology Co., Ltd. | Non-woven fabric reinforced microporous polymer membrane, manufacturing method and use thereof |
CN110227052A (zh) * | 2019-06-19 | 2019-09-13 | 杭州悦萱堂化妆品有限公司 | 一种保湿修复面霜及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113244122A (zh) | 2021-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0507272B1 (en) | Hair cosmetic composition comprising a water soluble chitin derivative and a polyphenol | |
DE69600153T2 (de) | Kosmetische Zusammensetzung die zur Fixierung und/oder Festigung geeignet ist und die ein bestimmtes Acrylcopolymer enthält | |
CN104000749B (zh) | 一种头皮护理液 | |
JPH10121030A (ja) | ポリマーレオロジー調節剤 | |
JPH10120526A (ja) | 増粘されたパーソナルケア組成物 | |
CN112494406A (zh) | 一种美白祛斑化妆品及其制备方法 | |
CN107260626B (zh) | 一种具有长效保湿作用的组合物及其制备方法 | |
CN111991261B (zh) | 一种适用于敏感头皮的温和控油洗发水组合物及其制备方法 | |
CN110025528A (zh) | 一种不含去离子水的抗氧化美白精华液及其制备方法 | |
CN114452235B (zh) | 一种鳄梨油洁面泡泡及其制备方法 | |
CN110680765A (zh) | 一种抗糖化精华及其制备方法 | |
EP1927378A1 (de) | Quercetin enthaltendes Haarbehandlungsmittel und dessen Verwendung zur Vitalizierung von Haaren | |
CN113244122B (zh) | 一种双组份精华面霜 | |
CN106619379B (zh) | 一种含植物发酵产物的组合物及其制备方法和应用 | |
JP2015013842A (ja) | 毛髪化粧料 | |
JP2009191046A (ja) | 毛髪化粧料 | |
DE19823552A1 (de) | Zubereitung zur Behandlung der menschlichen Haut und der menschlichen Haare mit einer speziellen Wirkstoffkombination sowie Verwendung dieser Wirkstoffkombination | |
CN112587426A (zh) | 一种美白祛斑精华液及其制备方法 | |
CN110917047B (zh) | 一种泡沫质量好的洁面泥及其制备方法 | |
EP2457556B1 (de) | Haarbehandlungsmittel | |
CN115068389B (zh) | 一种多效组合物、精华霜及其制备方法 | |
KR101878941B1 (ko) | 산삼배양근 발효물을 포함하는 나노에멀젼의 제조방법 및 이를 함유하는 피부미백용 화장료 조성물 | |
CN112426391B (zh) | 一种壳聚糖滋养润肤沐浴露及其制备方法 | |
CN111870558A (zh) | 一种抑制透明质酸酶活性的组合物及皮肤护理产品 | |
CN110840766A (zh) | 一种美白保湿氨基酸洁面乳及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |